Shanghai ERP Biotechnology: difference between revisions
Diff·revision 19 → 20·09:39, 27 Aug 2025
Difference between revision 19 and revision 20 of Shanghai ERP Biotechnology. 8 lines changed; the page grew by 384 bytes.
| Revision 19 — 02:08, 24 Aug 2025 ArchiveBot (talk) bot: normalise citation format 4,909 bytes +762 | Revision 20 — 09:39, 27 Aug 2025 LedgerLysander (talk) ce, tighten prose 5,293 bytes +384 | ||
|---|---|---|---|
| 30 | Purchaser reports describe conventional practice: lyophilised material in crimped vials, batch certificate with purity and appearance, insulated packaging on the incretin lines.{{r|reports}} Water figures have appeared on a minority of the submitted certificates.{{r|usp1503}} | 30 | Purchaser reports describe conventional practice: lyophilised material in crimped vials, batch certificate with purity and appearance, insulated packaging on the incretin lines.{{r|reports}} Water figures have appeared on a minority of the submitted certificates.{{r|usp1503}} |
| 31 | 31 | ||
| + | 32 | == Product range == | |
| + | 33 | | Class | Representative listings | Documentation reported | | |
| + | 34 | |---|---|---| | |
| + | 35 | | Incretin analogues | Semaglutide, tirzepatide, retatrutide | Certificate, purity; water on a minority | | |
| + | 36 | | Research peptides | Repair and secretagogue peptides | Certificate, purity | | |
| + | 37 | | SARMs | Bulk | Certificate, purity | | |
| + | 38 | | Raw materials and oils | Bulk | Certificate, limited detail | | |
| + | 39 | ||
| 32 | == References == | 40 | == References == |
| 33 | {{reflist}} | 41 | {{reflist}} |